+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field



Bacteriological, pharmacokinetic and clinical studies of SY5555 dry syrup in the pediatric field



Japanese Journal of Antibiotics 48(1): 71-91



Bacteriological, pharmacokinetic and clinical studies on SY5555 dry syrup (powder which is dissolved before use), a new penem antibiotic for oral use, were performed. The following results were obtained. 1. Antibacterial activities MICs of SY5555, clavulanic acid/amoxicillin (CVA/AMPC), cefotiam (CTM), cefpodoxime (CPDX), cefaclor (CCL) and cefdinir (CFDN) were determined against clinically isolated Staphylococcus aureus, coagulase negative staphylococci, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli and Enterobacter cloacae at a dose of 10-6 CFU/ml. MICs of SY5555 against S. aureus, CNS, S. pneumoniae, S. pyogenes, H. influenzae, M. catarrhalis, E. coli and E. cloacae were 0.2, 0.2, 0.2, ltoreq 0.025, 0.78, 0.2, 0.78 and 3.13 mu-g/ml, respectively, showing excellent antibacterial effects on these pathogens. Although the effects of SY5555 against H. influenzae and E. coli were slightly inferior to those of CPDX and CFDN, the drug showed the most excellent antibacterial effect on other strains as compared with the control drugs. 2. Absorption and excretion In this study, plasma concentrations and urinary recovery rates were examined after administration of SY5555 at doses of 5 and 10 mg/kg (potency) after meals. With both 5 and 10 mg/kg doses, peak plasma concentrations were reached 1 hour after administration, at 0.25 apprx 2.61 mu-g/ml (mean 1.47 mu-g/ml) and 1.08 apprx 2.17 mu-g/ml (mean 1.74 mu-g/ml), respectively. The plasma levels rapidly decreased to 0.06-0.19 mu-g/ml (0.12 mu-g/ml) and 0.0503 apprx 0.0637 mu-g/ml (0.057 mu-g/ml) after 6 hours. The half-lives 1.12 hours in the 5 mg/kg group and 1.0 hour in the 10 mg/kg group. The urinary recovery rates were determined in the first 8 hours after administration in the 5 mg/kg and 6 hours in the 10 mg/kg group, and the values were as low as 1.05 apprx 12.3% and 1.6 apprx 4.33%, respectively. 3. Clinical results The clinical responses were examined in a total of 73 cases including 4 acute pneumonia, 13 acute bronchitis, 11 tonsillitis, 3 pharyngitis, 12 scarlet fever, 2 pertussis, 6 urinary tract infection, 6 otitis media, 7 lymphadenitis, 2 staphylococcal scalded skin syndrome, 2 phlegmon, 4 impetigo and 1 purulent parotitis. The treatment was effective or better in 66 of 70 cases with an efficacy rate of 94.3% (3 undeterminable cases were excluded). Bacteriological effects were examined during the clinical course for detected or suspected pathogens found before administration of SY5555. The effects were determined in 50 cases including 7 cases of polymicrobacterial infections, 57 strains in total. Eight strains, however, persisted, hence the overall eradication rate was 86.0%. Because of the persistence of eight strains, the bacteriological efficacy rate was 84.0% (42/50). Except for mild watery stool which appeared in 1 case, no adverse reactions or abnormal laboratory test values were observed in any case.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 008211947

Download citation: RISBibTeXText

PMID: 7699846


Related references

Pharmacokinetic, bacteriological and clinical studies of SY5555 in the pediatric field. Japanese Journal of Antibiotics 48(2): 238-260, 1995

Bacteriological pharmacokinetic and clinical studies on rokitamycin dry syrup in the pediatric field. Japanese Journal of Antibiotics 41(6): 720-738, 1988

Bacteriological and clinical studies of SY5555 in pediatric field. Japanese Journal of Antibiotics 48(2): 191-199, 1995

Pharmacokinetic and clinical studies of SY5555 in the pediatric field. Japanese Journal of Antibiotics 47(4): 383-408, 1994

Pharmacokinetic and clinical studies on SY5555 dry syrup in children. Japanese Journal of Antibiotics 48(2): 261-270, 1995

Clinical study of SY5555 dry syrup in the pediatric field. Japanese Journal of Antibiotics 48(2): 205-209, 1995

Pharmacokinetic, bacteriological, and clinical studies on SY5555 in children. Japanese Journal of Antibiotics 48(1): 31-40, 1995

Microbiological, pharmacokinetic and clinical studies of rokitamycin dry syrup in the pediatric field. Japanese Journal of Antibiotics 41(7): 920-959, 1988

Pharmacokinetic, bacteriological and clinical studies on cefozopran in the pediatric field. Japanese Journal of Antibiotics 47(11): 1589-1611, 1994

Pharmacokinetic, bacteriological and clinical studies in the pediatric field on clarithromycin. Japanese Journal of Antibiotics 42(2): 281-303, 1989

Pharmacokinetic, bacteriological and clinical studies in the pediatric field on norfloxacin. Japanese Journal of Antibiotics 43(5): 799-807, 1990

Bacteriological pharmacokinetic and clinical studies on aztreonam in the pediatric field. Japanese Journal of Antibiotics 38(11): 3195-3216, 1985

Bacteriological, pharmacokinetic and clinical studies on biapenem (L-627) in the pediatric field. Japanese Journal of Antibiotics 47(12): 1728-1752, 1994

Bacteriological, pharmacokinetic and clinical studies of sulbactam/ampicillin in the pediatric field. Japanese Journal of Antibiotics 42(3): 719-724, 1989

Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field. Japanese Journal of Antibiotics 45(1): 48-73, 1992